Design, synthesis and biological evaluation of 2-aminopyrimidinones and their 6-aza-analogs as a new class of CK2 inhibitors

References

• Volynets GP, Golub AG, Bdzhola VG, et al. The role of protein kinase CK2 in the process of oncogenesis, regulation of apoptosis and cellular stress response. Ukr Bioorg Acta 2007;2:25–32
   Google Scholar
• Ruzzene M, Pinna LA. Addiction to protein kinase CK2: a common denominator of diverse cancer cells? Biochim Biophys Acta 2010;3:499–504
   Web of Science ®Google Scholar
• Landesman-Bollag E, Romieu-Mourez R, Song DH, et al. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001;20:3247–57
   PubMed Web of Science ®Google Scholar
• Lin YC, Hung MS, Lin CK, et al. CK2 inhibitors enhance the radio sensitivity of human non-small cell lung cancer cells through inhibition of stat3 activation. Cancer Biother Radiopharm 2011;26:381–8
   PubMed Web of Science ®Google Scholar
• Laramas M, Pasquier D, Filhol O, et al. Nuclear localization of protein kinase CK2 catalytic subunit (CK2-alpha) is associated with poor prognostic factors in human prostate cancer. Eur J Cancer 2007;43:928–34
   PubMed Web of Science ®Google Scholar
• Zou J, Luo H, Zeng Q, et al. Protein kinase CK2α is overexpressed in colorectal cancer and modulates cell proliferation and invasion via regulating EMT-related genes. J Transl Med 2011;9:97
   PubMed Web of Science ®Google Scholar
• Stalter G, Siemer S, Becht E, et al. Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochem Biophys Res Commun 1994;202:141–7
   PubMed Web of Science ®Google Scholar
• Piazza F, Manni S, Ruzzene M, et al. Protein kinase CK2 in hematologic malignancies: reliance on a pivotal cell survival regulator by oncogenic signaling pathways. Leukemia 2012;26:1174–9
   PubMed Web of Science ®Google Scholar
• Singh NN, Ramji DP. Protein kinase CK2, an important regulator of the inflammatory response? J Mol Med (Berl) 2008;86:887–97
   PubMed Web of Science ®Google Scholar
• Ivanov KI, Puustinen P, Gabrenaite R, et al. Phosphorylation of the potyvirus capsid protein by protein kinase CK2 and its relevance for virus infection. Plant Cell 2003;15:2124–39
   PubMed Web of Science ®Google Scholar
• Cozza G, Pinna LA, Moro S. Protein kinase CK2 inhibitors: a patent review. Expert Opin Ther Pat 2012;22:1081–97
   PubMed Web of Science ®Google Scholar
• Kotey IM, Balanda AO, Bdzhola VG, et al. Synthesis and biological evaluation of thienopyrimidinones as CK2 protein kinase inhibitors. Ukr Bioorg Acta 2008;2:3–9
   Google Scholar
• Pagano MA, Poletto G, Di Maira G, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. ChemBioChem 2007;8:129–39
   PubMed Web of Science ®Google Scholar
• Sarno S, De Moliner E, Ruzzene M, et al. Biochemical and three-dimensional-structural study of the specific inhibition of protein kinase CK2 by [5-oxo-5,6-dihydroindolo-(1,2-a)quinazolin-7-yl] acetic acid (IQA). Biochem J 2003;374:639–46
   PubMed Web of Science ®Google Scholar
• Golub AG, Yakovenko OY, Prykhod’ko AO, et al. Evaluation of 4,5,6,7-tetrahalogeno-1H-isoindole-1,3(2H)-diones as inhibitors of human protein kinase CK2. Biochim Biophys Acta 2008;1784:143–9
   PubMed Web of Science ®Google Scholar
• Golub AG, Yakovenko OY, Bdzhola VG, et al. Evaluation of 3-carboxy-4(1H)-quinolones as inhibitors of human protein kinase CK2. J Med Chem 2006;49:6443–50
   PubMed Web of Science ®Google Scholar
• Shoichet BK, Stroud RM, Santi DV, et al. Structure-based discovery of inhibitors of thymidylate synthase. Science 1993;259:1445–50
   PubMed Web of Science ®Google Scholar
• Bodian DL, Yamasaki RB, Buswell RL, et al. Inhibition of the fusion-inducing conformational change of influenza hemagglutinin by benzoquinones and hydroquinones. Biochemistry 1993;32:2967–78
   PubMed Web of Science ®Google Scholar
• Ring CS, Sun E, McKerrow JH, et al. Structure-based inhibitor design by using protein models for the development of antiparasitic agents. Proc Natl Acad Sci USA 1993;90:3583–7
   PubMed Web of Science ®Google Scholar
• Ewing TJ, Makino S, Skillman AG, et al. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des 2001;15:411–28
   PubMed Web of Science ®Google Scholar
• Yakovenko OY, Oliferenko AA, Golub AG, et al. The new method of distribution integrals evaluations for high throughput virtual screening. Ukr Bioorg Acta 2007;1:52–62
   Google Scholar
• Yakovenko OY, Li YY, Oliferenko AA, et al. Ab initio parameterization of YFF1, a universal force field for drug-design applications. J Mol Model 2012;18:663–73
   PubMed Web of Science ®Google Scholar
• Yakovenko OY, Oliferenko AA, Bdzhola VG, et al. Kirchhoff atomic charges fitted to multipole moments: implementation for a virtual screening system. J Comput Chem 2008;29:1332–43
   PubMed Web of Science ®Google Scholar
• Lindahl E, Hess B, van der Spoel D. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Mod 2001;7:306–17
   Web of Science ®Google Scholar
• Prykhod’ko AO, Yakovenko OY, Golub AG, et al. Evaluation of 4H-4-chromenone derivatives as inhibitors of protein kinase CK2. Biopolym Cell 2005;21:1–6
   Google Scholar
• Meggio F, Pagano M, Moro S, et al. Inhibition of protein kinase CK2 by condensed polyphenolic derivatives. An in vitro and in vivo study. Biochemistry 2004;43:12931–6
   PubMed Web of Science ®Google Scholar
• Chekanov MO, Tarnavskiy SS, Synyugin AR, et al. Solution phase combinatorial synthesis of a diverse library of 2-aminopyrimidinones and their 6-aza-analogs. Ukr Bioorg Acta 2011;10:29–40
   Google Scholar
• Ewing TJ, Kuntz ID. Critical evaluation of search algorithms for automated molecular docking and database screening. J Comput Chem 1996;18:1175–89
   Web of Science ®Google Scholar
• Suzuki Ya, Oishi Sh, Takei Y, et al. Design and synthesis of a novel class of CK2 inhibitors: application of copper- and gold-catalysed cascade reactions for fused nitrogen heterocycles. Org Biomol Chem 2012;10:4907--15
   PubMed Web of Science ®Google Scholar
• Fuchi N, Iura Y, Kaneko H, et al. Discovery and structure–activity relationship of 2,6-disubstituted pyrazines, potent and selective inhibitors of protein kinase CK2. Bioorg Med Chem Lett 2012;22:4358–61
   PubMed Web of Science ®Google Scholar
• Golub AG, Bdzhola VG, Briukhovetska NV, et al. Synthesis and biological evaluation of substituted (thieno[2,3-d]pyrimidin-4-ylthio)carboxylic acids as inhibitors of human protein kinase CK2. Eur J Med Chem 2011;46:870–6
   PubMed Web of Science ®Google Scholar
• Golub AG, Bdzhola VG, Kyshenia YV, et al. Structure-based discovery of novel flavonol inhibitors of human protein kinase CK2. Mol Cell Biochem 2011;356:107–15
   PubMed Web of Science ®Google Scholar
• Ferguson AD, Sheth PR, Basso AD, et al. Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett 2011;585:104–10
   PubMed Web of Science ®Google Scholar
• Backes AC, Zech B, Felber B, et al. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition. Expert Opin Drug Discov 2008;3:1409–25
   PubMed Web of Science ®Google Scholar
• Instant JChem, release version 5.5.1. ChemAxon. Available from: http://www.chemaxon.com
   Google Scholar